🧾 What This Document Is

This is Adlai Nortye's annual report (Form 20-F) for the year ended December 31, 2025. It's a comprehensive filing required by the U.S. SEC for foreign companies listed on American exchanges. Think of it as the company's official "year-in-review" and health check-up, packed with detailed financial data, business descriptions, and a very long list of potential risks.

👉 In simple terms: This document tells investors everything they need to know about what the company did last year, how much money it made or lost, and what could go wrong in the future.

🏢 What The Company Does

Adlai Nortye is a clinical-stage biopharmaceutical company. In simple terms, they are a drug development startup focused on discovering and developing new medicines for cancer (oncology). They don't have any products on the market yet and are still in the expensive research and trial phase.

• Business Model: They combine internal research with licensing drug candidates from other companies. Their goal is to develop these drugs, get them approved by regulators like the FDA (U.S.) and NMPA (China), and then commercialize them.
• Key Structure: They are a Cayman Islands holding company with main operations in China (via Hangzhou Adlai) and the U.S. (in New Jersey).
• Listed On: The Nasdaq Global Market under the ticker ANL. Each American Depositary Share (ADS) represents three of their Class A ordinary shares.

💰 Financial Highlights (The Numbers Story)

This section shows the classic financial profile of a research-heavy biotech startup: significant investment and losses while chasing future breakthroughs.

• Net Losses: The company is not profitable. Its net losses were:

  • 2023: US$109.2 million (revised)
  • 2024: US$51.9 million
  • 2025: US$35.5 million 👉 Why it matters: Losses are decreasing, which could mean they are managing costs better, but they are still burning cash to fund research.

• Cash Burn: They spend a lot of cash on operations. Net cash used in operating activities was:

  • 2023: US$56.7 million
  • 2024: US$51.8 million
  • 2025: US$33.5 million

• Working Capital Problem (⚠️ Major Red Flag): As of December 31, 2025, the company had a working capital deficiency of US$14.7 million. This means its short-term liabilities exceeded its short-term assets. They also reported net liabilities of US$8.3 million. 👉 Why it matters: This is a serious financial warning sign. It means the company could struggle to pay its immediate bills and may need to raise more money soon, which could dilute existing shareholders.

⚠️ Major Risks & Challenges (The "What Could Go Wrong" List)

The filing dedicates dozens of pages to risks. Here are the most critical ones for an investor to understand:

• Material Weakness in Controls: The company identified a "material weakness" in its internal controls over financial reporting. This means there's a significant risk its financial statements could have errors.
• Funding Dependency: They have a limited operating history, have never made a profit, and expect continued losses. They explicitly say they may need additional financing to fund development and commercialization, and it might not be available.
• Single-Product Focus & Trial Risk: Their success hinges on a small number of drug candidates failing or succeeding in clinical trials. Failure would be devastating.
• Geopolitical & Regulatory Risk: Operating between China and the U.S. exposes them to trade tensions, data transfer restrictions, and complex, differing regulations in both countries.
• PRC-Specific Risks: They are subject to evolving Chinese regulations on overseas listings, cybersecurity, and data management, which could impact their operations and structure.

🚀 Key Moves & Strategy

While the filing is heavy on risks, it outlines the company's path forward:

• Advancing Pipeline: Their primary focus is advancing their clinical-stage drug candidates through trials.
• Global Clinical Trials: They are conducting trials across multiple countries (U.S., Europe, Asia, etc.), which is necessary for global approvals but adds complexity and cost.
• Preparing for Commercialization: While pre-revenue, they are building infrastructure and planning for the day they might get a drug approved, which involves high costs for manufacturing, marketing, and sales.

📦 Financial Position Snapshot

Beyond the working capital issue, here's a quick look at their finances:

• Accounting Standards: They use International Financial Reporting Standards (IFRS), not U.S. GAAP.
• Government Grants: They received US$1.4 million in government grants in 2025, down from US$3.3 million in 2023. They note that these incentives are discretionary and could change.
• Share Count: As of Dec 31, 2025, there were 120,000,803 ordinary shares outstanding (103 million Class A and 17 million Class B).

🔮 What's Next

The company's future is a high-stakes race:

1. Use remaining cash to fund ongoing clinical trials.
2. Seek regulatory approvals for drug candidates that show success.
3. Likely need to raise more capital (through selling shares or debt) to fund the extremely expensive process of late-stage trials and commercial launch.
4. Navigate intense regulatory scrutiny in both the U.S. and China.

⚖️ The Big Picture: Strengths & Risks

👍 Potential Strengths:

• Focused on the high-demand area of oncology.
• Has active clinical trials, showing operational progress.
• Losses are trending downward year-over-year.

⚠️ Overwhelming Risks:

• Financial Fragility: Working capital deficiency and net liabilities are immediate threats.
• Execution Risk: Drug development is notoriously difficult, expensive, and prone to failure.
• Regulatory Maze: Success requires passing the strictest regulatory bodies in two major, politically tense countries.
• Cash Burn: The company is a money-consuming engine with no revenue in sight.

🧠 The Analogy

Adlai Nortye is like a high-stakes explorer building a bridge to a new island (a cancer cure). They have a promising map (their drug candidates) and a skilled crew (their R&D team). However, their boat is leaking (working capital deficiency), they're running out of supplies (cash burn), and they're building the bridge through a stormy strait between two powerful, quarreling nations (U.S.-China relations). Success means reaching a treasure island; failure means being lost at sea.

🧩 Final Takeaway

Adlai Nortye is a classic high-risk, high-reward biotech bet. Investors are essentially funding a bet on its science and its ability to navigate immense financial and geopolitical hurdles. The critical near-term issue is its fragile financial health and the strong likelihood it will need to raise more money, which could significantly impact shareholder value. This is not for the faint of heart.